SCS Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

SCS Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.57M	Buy	12,257 +187	+2%	+$23.3K	0.02%	224
2025 Q4	$1.47M	Sell	12,070 -9,562	-44%	-$1.1M	0.02%	242
2025 Q3	$2.17M	Buy	21,632 +4	+0%	+$360	0.02%	209
2025 Q2	$1.79M	Sell	21,628 -999	-4%	-$79.7K	0.02%	232
2025 Q1	$1.84M	Buy	+22,627	New	+$2.02M	0.02%	210

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SCS Capital Management's XBI Position: Q1 2026 in Review

SCS Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 1.5% in Q1 2026, buying an estimated $23.3K and bringing the position to 12,257 shares worth $1.57M. The position accounts for 0.02% of the portfolio, ranked #224.

SCS Capital Management first reported a position in XBI in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.17M in Q3 2025. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

SCS Capital Management held 12,257 shares of State Street SPDR S&P Biotech ETF worth $1.57M as of Q1 2026.
SCS Capital Management bought 187 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $23.3K.
State Street SPDR S&P Biotech ETF made up 0.02% of SCS Capital Management's portfolio in Q1 2026, its #224 holding.
SCS Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2025 and has held it in 5 quarters since.
SCS Capital Management's State Street SPDR S&P Biotech ETF position peaked at $2.17M in Q3 2025.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on SCS Capital Management's 13F filing for Q1 2026, filed 11 May 2026.